Advertisement

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




May
13
Today In Oncology
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings
Recent Rates of Systemic Treatment for Metastatic NSCLC in Older Adults
Whole-Genome Sequencing Test Enables Genomically Informed Treatment Decision-Making in Multiple Myeloma
Early-Onset Lung Cancer May Be Connected to Pesticide Contaminants
Noninvasive Urine Test May Provide Grade Group Information in Patients With Prostate Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo